TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Should You Buy Viking Therapeutics Before Nov. 5?

The Motley Fool Logo The Motley Fool By Adria Cimino
Should You Buy Viking Therapeutics Before Nov. 5?

Viking Therapeutics is developing a promising weight loss drug (VK2735) in phase 3 trials, targeting the rapidly growing obesity drug market. The company has shown potential with clinical trial results indicating up to 13.1% average weight loss, and is presenting research at upcoming medical conferences.

Insights
VKTX   positive

Strong clinical trial results, promising drug candidate in a growing market, potential to compete with major pharmaceutical companies